2.31
price up icon3.12%   0.07
 
loading
Immunitybio Inc stock is traded at $2.31, with a volume of 9.52M. It is up +3.12% in the last 24 hours and down -14.76% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.24
Open:
$2.24
24h Volume:
9.52M
Relative Volume:
1.09
Market Cap:
$2.18B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.3814
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-9.41%
1M Performance:
-14.76%
6M Performance:
-32.46%
1Y Performance:
-44.47%
1-Day Range:
Value
$2.23
$2.35
1-Week Range:
Value
$2.17
$2.55
52-Week Range:
Value
$1.83
$7.48

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
685
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.31 2.30B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
Aug 20, 2025

ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN

Aug 20, 2025
pulisher
Aug 19, 2025

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - BioSpace

Aug 19, 2025
pulisher
Aug 19, 2025

ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView

Aug 19, 2025
pulisher
Aug 19, 2025

Q2 2025 CRO Activity and Intel Report Featuring ICON, AstraZeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, BoryungResearchAndMarkets.com - FinancialContent

Aug 19, 2025
pulisher
Aug 19, 2025

ImmunityBio Launching New Phase 2 Trial of Anktiva to Treat Long COVID - MarketScreener

Aug 19, 2025
pulisher
Aug 19, 2025

ImmunityBio launches phase 2 study of ANKTIVA for long COVID - Investing.com

Aug 19, 2025
pulisher
Aug 18, 2025

ImmunityBio Inc. Stock Flags Risk Zone in Volatility IndexJuly 2025 EndofMonth & Entry Point Confirmation Signals - sundaytimes.kr

Aug 18, 2025
pulisher
Aug 18, 2025

ImmunityBio Wins U.K. Approval - Los Angeles Business Journal

Aug 18, 2025
pulisher
Aug 17, 2025

Fibonacci Retracement Aligns with Support in ImmunityBio Inc.July 2025 News Drivers & Fast Momentum Entry Tips - newsimpact.co.kr

Aug 17, 2025
pulisher
Aug 17, 2025

Published on: 2025-08-17 09:14:13 - metal.it

Aug 17, 2025
pulisher
Aug 16, 2025

Heatmap Data Shows High Activity in ImmunityBio Inc. Sector2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - sundaytimes.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Is ImmunityBio Inc.’s growth already priced inMarket Performance Recap & AI Powered Market Trend Analysis - thegnnews.com

Aug 16, 2025
pulisher
Aug 15, 2025

Is ImmunityBio Inc. a speculative investmentTrade Volume Report & Fast Gain Swing Alerts - sundaytimes.kr

Aug 15, 2025
pulisher
Aug 15, 2025

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter - Oncodaily

Aug 15, 2025
pulisher
Aug 15, 2025

ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView

Aug 15, 2025
pulisher
Aug 15, 2025

Is ImmunityBio Inc. stock a value trap2025 Valuation Update & Expert Verified Stock Movement Alerts - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - ADVFN Brasil

Aug 15, 2025
pulisher
Aug 14, 2025

RSI + MACD Show Convergence for ImmunityBio Inc.2025 Price Targets & Growth Focused Stock Pick Reports - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

ImmunityBio shares fall 1.95% intraday after Q2 net loss and revenue rise. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials - simplywall.st

Aug 14, 2025
pulisher
Aug 14, 2025

ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN

Aug 14, 2025
pulisher
Aug 14, 2025

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - BioSpace

Aug 14, 2025
pulisher
Aug 13, 2025

ImmunityBio stock surges on promising trial results for lymphoma treatment, analysts forecast significant upside potential. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment - MarketScreener

Aug 13, 2025
pulisher
Aug 13, 2025

Hillenbrand, ImmunityBio, V2X - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio Surges 15% on Groundbreaking Cancer Trial Results: A New Era for NK Cell Therapy? - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio announces early findings from QUILT-106 trial - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success - StocksToTrade

Aug 13, 2025
pulisher
Aug 13, 2025

Lumentum Holdings, ImmunityBio, V2X - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio Stock Surges on Robust Q2 Earnings Report - timothysykes.com

Aug 13, 2025
pulisher
Aug 13, 2025

Immunitybio stock soars after promising cancer therapy trial results By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio's NK cell therapy shows promise in lymphoma trial. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ) - Seeking Alpha

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio rises after early data for blood cancer cell therapy - TradingView

Aug 13, 2025
pulisher
Aug 13, 2025

ImmunityBio’s Stock Surges on Promising Trial Results - TipRanks

Aug 13, 2025
pulisher
Aug 13, 2025

CD19 CAR-NK therapy shows complete responses in late-stage lymphoma - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Vax-Before-Travel

Aug 13, 2025
pulisher
Aug 12, 2025

ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer. - AInvest

Aug 12, 2025
pulisher
Aug 11, 2025

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - MarketScreener

Aug 11, 2025
pulisher
Aug 09, 2025

ImmunityBio’s Shareholder Settlement Gains Preliminary Approval - The Globe and Mail

Aug 09, 2025
pulisher
Aug 09, 2025

ImmunityBio Shareholder Settlement Gains Preliminary Approval, Boosting Company's Future Prospects - AInvest

Aug 09, 2025
pulisher
Aug 07, 2025

Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Why Investors Shouldn't Be Surprised By ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings Beat: ImmunityBio, Inc. (NASDAQ:IBRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

Aug 07, 2025
pulisher
Aug 07, 2025

Q2 2025 Revenue Up 5% YoY to $1,241mln; Raises FY23 Guidance, Innovation Target. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

ImmunityBio Q2 Earnings Show 60% Revenue Growth, $153.7 Million in Cash, and Strong Sales Momentum. - AInvest

Aug 07, 2025
pulisher
Aug 06, 2025

ImmunityBio's ANKTIVA Receives Buy Rating Amid Expanding Oncology Potential and Market Growth - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

ImmunityBio Reports Q2 Earnings with 60% Revenue Increase, $43M in Sales, and 246% Unit Growth - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

ImmunityBio 2025 Q2 Earnings Sustained Losses Amid Strong Revenue Surge - AInvest

Aug 06, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
SOON-SHIONG PATRICK
See remarks
Feb 22 '25
Option Exercise
0.00
114,329
0
29,588,261
Sachs David C.
Chief Financial Officer
Feb 22 '25
Option Exercise
0.00
40,650
0
241,480
Adcock Richard
CEO & President
Feb 22 '25
Option Exercise
0.00
152,439
0
412,585
Simon Barry J.
Director
Feb 22 '25
Option Exercise
0.00
15,243
0
3,249,024
Simon Barry J.
Director
Jan 22 '25
Option Exercise
2.00
110,020
219,864
3,233,781
Adcock Richard
CEO & President
Dec 31 '24
Option Exercise
0.00
34,483
0
277,621
Sachs David C.
Chief Financial Officer
Dec 31 '24
Option Exercise
0.00
30,397
0
216,235
LAUER REGAN J
Chief Accounting Officer
Dec 15 '24
Option Exercise
0.00
21,031
0
115,365
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):